𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer

✍ Scribed by Yoh Watanabe; Eiji Koike; Hidekatsu Nakai; Tomomaro Etoh; Hiroshi Hoshiai

Publisher
Springer
Year
2008
Tongue
English
Weight
237 KB
Volume
13
Category
Article
ISSN
1341-9625

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of ecteinascidin 743 in h
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
✍ Caroline Laverdiere; E. Anders Kolb; Jeffrey G. Supko; Richard Gorlick; Paul A. πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 108 KB

## Abstract ## BACKGROUND Recurrent osteosarcoma is a drug‐resistant disease with a dismal prognosis. The objective of this Phase II study was to evaluate the activity of ecteinascidin 743 (ET‐743) as a salvage therapy in these patients. ## METHODS Patients with recurrent osteosarcoma who had re

A phase II and pharmacodynamic study of
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer
✍ Edwin M. Posadas; Meghan S. Liel; Virginia Kwitkowski; Lori Minasian; Andrew K. πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 145 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The primary objective of this study was to evaluate the biochemical effects of gefitinib on its target signal‐transduction pathways in patients with recurrent epithelial ovarian cancer (EOC). The secondary objectives included assessing clinical activity and toxicity and d